Pro-Pharmaceuticals, Inc. Updates Progress of Clinical Trials & DAVANAT(R) 505 (b)(2) Filings

NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), a company “Advancing Drugs Through Glycoscience®”, today updated the progress of its Phase II clinical trial for first-line treatment of metastatic, unresectable colorectal cancer patients who are unable to tolerate irinotecan and/or oxaliplatin, and its Phase II clinical trial for first-line treatment of biliary cancer patients. Treatment for both indications may represent orphan drug status for DAVANAT®, the Company’s target delivery compound. In addition, the Company plans to submit the manufacturing data requested by the FDA this year for DAVANAT® 505 (b)(2) filings as a functional excipient.

MORE ON THIS TOPIC